France· FR:69520409
TEPKINLY 4 mg/0,8 mL, solution injectable
A epcoritamab product containing épcoritamab, registered in France by ABBVIE DEUTSCHLAND (ALLEMAGNE). The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Epcoritamab is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FX27 (epcoritamab), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Epcoritamab · ATC L01FX27
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of epcoritamab costs, country by country.
Normalised to the WHO defined daily dose (1.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Epcoritamab · price per daily dose (1.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$281.38
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ÉPCORITAMAB
- Manufacturer
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- L01FX27
- ATC class
- Epcoritamab
- Defined daily dose
- 1.7 mg, P
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550969551 flacon en verre de 0,8 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Epcoritamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesEPKINLYGenmab US, Inc.
- CanadaEPKINLYABBVIE CORPORATION
- SwitzerlandTepkinly 4 mg/0,8 ml, InjektionslösungAbbVie AG
- CzechiaTEPKINLYAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainTEPKINLY 4 MG/0,8 ML SOLUCION INYECTABLEAbbvie Deutschland Gmbh & Co. Kg
- FinlandTepkinlyAbbVie Deutschland GmbH&Co.KG
- United KingdomTepkinly 48mg/0.8ml solution for injection vialsAbbVie Ltd
- BelgiumTepkinly 4 mg/0.8 mlAbbVie Deutschland
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Tepkinly
- Iceland · Tepkinly
- Liechtenstein · Tepkinly
- Norway · Tepkinly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9d42b6f5-4585-4d2e-bddd-1dcc62435cf2 GET /v1/drugs/9d42b6f5-4585-4d2e-bddd-1dcc62435cf2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69520409",
"date_amm": "2023-09-22",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1759",
"substance": "ÉPCORITAMAB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about epcoritamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.